Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway

Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response

(2023) Milad Ashrafizadeh et al.   MEDICINAL RESEARCH REVIEWS

JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells

(2022) Yunmoon Oh et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pacritinib Inhibition of IRAK1 Blocks Aberrant TLR8 Signalling by SARS-CoV-2 and HIV-1-Derived RNA

(2022) Grant R. Campbell et al.   Journal of Innate Immunity

JAK: Not Just Another Kinase

(2022) Ruchi P. Agashe et al.   MOLECULAR CANCER THERAPEUTICS

Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia

(2022) John Mascarenhas   Expert Review of Hematology

Optimization of first‐line systemic therapy in patients with advanced clear cell renal cell carcinoma

(2022) Toshio Takagi   INTERNATIONAL JOURNAL OF UROLOGY

Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma

(2021) Lizhen Liu et al.   CANCER RESEARCH

Dual relationship between long non-coding RNAs and STAT3 signaling in different cancers: New insight to proliferation and metastasis

(2021) Milad Ashrafizadeh et al.   LIFE SCIENCES

Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma

(2021) Nathaniel R. Wilson et al.   Clinical Genitourinary Cancer

STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects

(2020) Milad Ashrafizadeh et al.   Biology-Basel

Targeting the HIF2–VEGF axis in renal cell carcinoma

(2020) Toni K. Choueiri et al.   NATURE MEDICINE

Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis

(2020) Daniel Doheny et al.   ONCOGENE

Targeting the JAK/STAT Signaling Pathway for Breast Cancer.

(2020) Fei Shao et al.   CURRENT MEDICINAL CHEMISTRY

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

(2020) Aaron T. Gerds et al.   Blood Advances

Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML

(2019) Jae Yoon Jeon et al.   INVESTIGATIONAL NEW DRUGS

Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation

(2019) Perner et al.   Cells

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes

(2018) Mona M. Hosseini et al.   LEUKEMIA

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies

(2018) Peter Makhov et al.   MOLECULAR CANCER THERAPEUTICS

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis

(2018) John Mascarenhas et al.   JAMA Oncology

The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model

(2017) Katharine Victoria Jensen et al.   PLoS One

Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer

(2016) Nobuaki Ochi et al.   EXPERIMENTAL CELL RESEARCH

Choosing the right cell line for renal cell cancer research

(2016) Klaudia K. Brodaczewska et al.   Molecular Cancer

Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action

(2016) I. Duran et al.   Targeted Oncology

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model

(2015) Bhagwan Yadav et al.   Computational and Structural Biotechnology Journal

Apoptosis-related BCL2-family Members: Key Players in Chemotherapy

(2014) Christos Kontos et al.   Anti-Cancer Agents in Medicinal Chemistry

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

(2012) Adrian Britschgi et al.   CANCER CELL

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

(2012) V Novotny-Diermayr et al.   Blood Cancer Journal

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

(2011) S Hart et al.   Blood Cancer Journal

Anchorage-independent cell growth signature identifies tumors with metastatic potential

(2009) S Mori et al.   ONCOGENE

The JAK kinases: Not just another kinase drug discovery target

(2008) Andrew F. Wilks   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY